Topic: Failed drug program
The lackluster results led Syros to switch its attention to an oral CDK7 inhibitor, SY-5609, that is due to enter the clinic early next year.
The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.
AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.
The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
A phase 3 trial of Vectura’s VR475 in patients with severe uncontrolled asthma has missed its primary endpoint.
An audit of Celgene’s R&D over the last five years has revealed that two-thirds of its programs failed.
Celldex culled another two R&D projects after its midstage failure in April, and now says it will focus its efforts mainly on two cancer antibodies.
Both drugs held up as the drivers for Allergan’s $639 million purchase of Vitae have now been dropped.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
The antibiotic cadazolid was one of two experimental assets J&J acquired in its $30 billion takeover of Actelion last year.